News

The FDA has approved Reyvow (lasmiditan) tablets for the acute treatment of migraine with or without aura in adults. This drug is not indicated for the preventive treatment of migraine and can cause driving impairment, which is why Reyvow is pending controlled substance scheduling.

Sandoz Inc. is voluntarily recalling all quantities and lots within expiry of Ranitidine hydrochloride capsules because of confirmed contamination with N-Nitrosodimethylamine (NDMA) above levels established by the FDA.

An Oklahoma judge has ruled that drug manufacturer Johnson & Johnson created a public nuisance in their deceptive marketing of opioid pain medications, helping to cause the state’s opioid crisis, and have been ordered to pay $572 million to the state.

The FDA has approved the first generic versions of Lyrica (pregabalin), granting approvals to a total of nine pharmaceutical companies for five different conditions, including the management of neuropathic pain associated with spinal cord injury.